Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Bladder Cancer Pipeline Drugs Market Report Overview
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections.
The Bladder Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects.
Bladder Cancer Pipeline Products Market Segmentation by Targets
The key targets in the Bladder Cancer pipeline products market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, DNA, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Nectin 4, and Tubulin, among others. Programmed Cell Death Protein 1 was the leading target in the pipeline.
Bladder Cancer Pipeline Products Market Analysis by Targets
For more target insights into the Bladder Cancer pipeline products market, download a free report sample
Bladder Cancer Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the Bladder Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Cytotoxic To Cells Expressing Nectin 4, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor, among others. Programmed Cell Death Protein 1 Antagonist was the leading MoA in the pipeline.
Bladder Cancer Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the Bladder Cancer pipeline products market, download a free report sample
Bladder Cancer Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the Bladder Cancer pipeline products market are intravenous, oral, intravesical, subcutaneous, intratumor, parenteral, intravenous drip, intraperitoneal, intramuscular, and intradermal, among others. Intravenous was the leading route of administration.
Bladder Cancer Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the Bladder Cancer pipeline products market, download a free report sample
Bladder Cancer Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the Bladder Cancer pipeline products market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Oncolytic Virus, Cell Therapy, Subunit Vaccine, Biologic, and Recombinant Protein, among others. Small molecule was the leading molecule in the pipeline.
Bladder Cancer Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the Bladder Cancer pipeline products market, download a free report sample
Bladder Cancer Pipeline Products Market - Competitive Landscape
Some of the leading companies in the Bladder Cancer pipeline products market are Johnson & Johnson, Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Pfizer Inc, F. Hoffmann-La Roche Ltd, Advenchen Laboratories LLC, BioAtla Inc, CG Oncology Inc, and Daiichi Sankyo Co Ltd. Johnson & Johnson is the leading company in the Bladder Cancer pipeline products market.
Bladder Cancer Pipeline Products Market Analysis by Companies
To know more about the leading players in the Bladder Cancer pipeline products market, download a free report sample
Bladder Cancer pipeline Products Market Report Overview
| Key Targets | Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, DNA, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Nectin 4, and Tubulin |
| Key Mechanisms of Action | Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Cytotoxic To Cells Expressing Nectin 4, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor |
| Key Routes of Administration | Intravenous, Oral, Intravesical, Subcutaneous, Intratumor, Parenteral, Intravenous Drip, Intraperitoneal, Intramuscular, and Intradermal |
| Key Molecule Type | Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Oncolytic Virus, Cell Therapy, Subunit Vaccine, Biologic, and Recombinant Protein |
| Leading Companies | Johnson & Johnson, Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Pfizer Inc, F. Hoffmann-La Roche Ltd, Advenchen Laboratories LLC, BioAtla Inc, CG Oncology Inc, and Daiichi Sankyo Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
4D Pharma Plc
4SC AG
A28 Therapeutics Inc
Aadi Bioscience Inc
AB Pharma Ltd
AbbVie Inc
Abivax SA
Acepodia Inc
Acrivon Therapeutics Inc
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advaxis Inc
Advenchen Laboratories LLC
Agenus Inc
Aktis Oncology Inc
Alligator Bioscience AB
Alloplex Biotherapeutics Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Amgen Inc
Amrita Therapeutics
Andes Biotechnologies
Angex Pharmaceutical Inc
Apexian Pharmaceuticals Inc
APIM Therapeutics AS
Apollomics Inc
Aprea Therapeutics Inc
Aravive Inc
Archivel Farma SL
Arcus Biosciences Inc
Asieris Pharmaceuticals Co Ltd
Aslan Pharmaceuticals Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aura Biosciences Inc
Aurigene Discovery Technologies Ltd
Aurora Oncology Inc
Avacta Life Sciences Ltd
AvenCell Europe GmbH
BacoCure
Bavarian Nordic AS
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
BerGenBio ASA
BeyondSpring Inc
Bicycle Therapeutics Plc
Bio-Thera Solutions Ltd
BioAtla Inc
Biocad
Biohaven Pharmaceutical Holding Company Ltd
BioMed Valley Discoveries Inc
Biomics Biotechnologies Co Ltd
BioNTech SE
Bioven Group
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bold Therapeutics Inc
Bolt Biotherapeutics Inc
BoYen Therapeutics Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Cantargia AB
Catalent Inc
Catalym GmbH
CDR-Life Inc
CellCentric Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Celprogen Inc
CG Oncology Inc
CheckPoint Immunology Inc
Chengdu Keen Biotechnology Co Ltd
CicloMed LLC
Clover Biopharmaceuticals Ltd
CMG Pharmaceutical Co Ltd
Codiak BioSciences Inc
Compass Therapeutics Inc
Convalife
Corvus Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Cugene Inc
Curigin Co Ltd
Cyclacel Pharmaceuticals Inc
Cytodyn Inc
CytoImmune Therapeutics Inc
CytomX Therapeutics Inc
D3 Bio Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dragonboat Biopharmaceutical (Shanghai) Co Ltd
Duet Therapeutics Inc
Ectin Research AB
Eddingpharm Inc
Eisai Co Ltd
Elevation Oncology Inc
Eli Lilly and Co
Elpis Biopharmaceuticals Corp
Elucida Oncology Inc
Emtora Biosciences
ENB Therapeutics LLC
enGene Inc
EpimAb Biotherapeutics Inc
Exelixis Inc
EXUMA Biotech Inc
F. Hoffmann-La Roche Ltd
Fidia farmaceutici SpA
FKD Therapies Oy
For-Robin Inc
Fujifilm Holdings Corp
Fusion Pharmaceuticals Inc
G1 Therapeutics Inc
Gene Signal International SA
Genentech USA Inc
Genexine Inc
Genmab AS
Gilead Sciences Inc
GLG Pharma SA
GlycoNex Inc
GlyTherix Ltd
GO Therapeutics Inc
Green Cross LabCell Corp
GSK plc
H3 Biomedicine Inc
Hamlet Pharma AB
Hangzhou DAC Biotech Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
Hefei Hankemab Biotechnology Co Ltd
Hope Biosciences LLC
Horizon Therapeutics Plc
HRYZ (ShenZhen) Biotech Co
Huabo Biopharm (Shanghai) Co Ltd
Hummingbird Bioscience Pte Ltd
Ideaya Biosciences Inc
Ikena Oncology Inc
ImCheck Therapeutics SAS
Immatics NV
ImmunityBio Inc
Immunomic Therapeutics Inc
ImmunSYS Inc
Immupharma Plc
Imugene Ltd
Imunon Inc
IMV Inc
Imvax Inc
Incanthera Plc
Incyte Corp
Indaptus Therapeutics Inc
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Intas Pharmaceuticals Ltd
Intravacc BV
Invectys SA
IO Biotech Inc
Iovance Biotherapeutics Inc
Istari Oncology Inc
Jacobio Pharmaceuticals Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
Keythera Pharmaceuticals Co Ltd
Komipharm International Co Ltd
Kyowa Kirin Co Ltd
Lantern Pharma Inc
Lepu Biopharma Co Ltd
Liangjiang Medicine Co Ltd
LIfT BioSciences Ltd
Lindis Biotech GmbH
Linnane Pharma AB
Lipac Oncology LLC
LipoMedix Pharmaceutical Inc
LipoSeuticals Inc
Longbow Immunotherapy Inc
Loxo Oncology Inc
Luye Pharma Group Ltd
Lycera Corp
Machavert Pharmaceuticals LLC
Manhattan Biosolutions Inc
MaxiVAX SA
MedAnnex Ltd
Medibiofarma SL
Medicenna Therapeutics Corp
Mediolanum farmaceutici SpA
Medivir AB
Medolife Rx Inc
MedPacto Inc
Merck & Co Inc
Merck KGaA
Midissia Therapeutics Inc
Mirati Therapeutics Inc
Moderna Inc
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech Inc
Morphogenesis Inc
MorphoSys AG
Morvus Technology Ltd
Mustang Bio Inc
NanoCarrier Co Ltd
Nanology LLC
NeoTX Therapeutics Ltd
NewG Lab Pharma Co Ltd
NewG Lab Pharma Inc
NGM Biopharmaceuticals Inc
Northwest Biotherapeutics Inc
NovaRock Biotherapeutics Inc
Novartis AG
NuGenerex Immuno-Oncology Inc
Ocellaris Pharma Inc
Ocuphire Pharma Inc
Ona Therapeutics SL
Oncorus Inc
OncoSTING LLC
Oncovir Inc
Ono Pharmaceutical Co Ltd
Optimum Therapeutics LLC
Oxford BioTherapeutics Ltd
Pact Pharma Inc
Pacylex Pharmaceuticals Inc
Pan Cancer T BV
Papyrus Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Pinotbio Inc
Plus Therapeutics Inc
Portage Biotech Inc
Potenza Therapeutics Inc
Prelude Therapeutics Inc
Prokarium Ltd
Propanc Biopharma Inc
Protara Therapeutics Inc
Provecs Medical GmbH
PsiOxus Therapeutics Ltd
Puma Biotechnology Inc
Qilu Pharmaceutical Co Ltd
Qu Biologics Inc
Quadriga BioSciences Inc
Qwixel Therapeutics LLC
Ractigen Therapeutics Inc
Rapa Therapeutics LLC
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Replimune Ltd
Sanofi
Sareum Holdings Plc
Savoy Pharmaceuticals Inc
Scholar Rock Inc
Seagen Inc
Serum Institute of India Pvt Ltd
Sesen Bio Inc
SetLance srl
Seven and Eight Biopharmaceuticals Corp
Shandong New Time Pharmaceutical Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Yuansong Biotechnology Co Ltd
Shenyang Research Institute of Chemical Industry Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shionogi & Co Ltd
Shorla Pharma Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Sillajen Biotherapeutics
Sirnaomics Ltd
SOTIO Biotech AS
Spectrum Pharmaceuticals Inc
Statera Biopharma Inc
Stcube Inc
Sumitomo Dainippon Pharma Oncology, Inc
Syncromune Inc
SynOx Therapeutics Ltd
T-Cure Bioscience Inc
TAE Life Sciences LLC
Takeda Pharmaceutical Co Ltd
Tango Therapeutics Inc
Targovax ASA
TCRx Therapeutics Co Ltd
Tempest Therapeutics Inc
Tessa Therapeutics Ltd
Theralase Technologies Inc
Tollys SAS
Toray Industries Inc
Transcenta Holding Ltd
Transgene SA
TransThera Sciences (Nanjing) Inc
Treos Bio Ltd
Tyra Biosciences Inc
UbiVac Inc
United Immunity Co Ltd
UroGen Pharma Ltd
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxiion Therapeutics Inc
Venenum Biodesign LLC
Vivlmmune Inc
Vyriad Inc
Wuhan Binhui Biotechnology Co Ltd
Xbrane Biopharma AB
Xiangxue Life Sciences
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhejiang Yangshengtang Biotech Co Ltd
Zhuhai Beihai Biotech Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Bladder Cancer pipeline products market?
The key targets in the Bladder Cancer pipeline products market are Programmed Cell Death Protein 1, Programmed Cell Death 1 Ligand 1, Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Fibroblast Growth Factor Receptor 3, Fibroblast Growth Factor Receptor 1, Fibroblast Growth Factor Receptor 2, DNA, Vascular Endothelial Growth Factor Receptor 2, Cells Expressing Nectin 4, and Tubulin, among others.
-
What are the key mechanisms of action in the Bladder Cancer pipeline products market?
The key mechanisms of action in the Bladder Cancer pipeline products market are Programmed Cell Death Protein 1 Antagonist, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, Fibroblast Growth Factor Receptor 3 Inhibitor, Fibroblast Growth Factor Receptor 1 Inhibitor, Fibroblast Growth Factor Receptor 2 Inhibitor, DNA Synthesis Inhibitor, Cytotoxic To Cells Expressing Nectin 4, Tubulin Inhibitor, and Vascular Endothelial Growth Factor Receptor 2 Inhibitor, among others.
-
What are the key routes of administration in the Bladder Cancer pipeline products market?
The key routes of administration in the Bladder Cancer pipeline products market are intravenous, oral, intravesical, subcutaneous, intratumor, parenteral, intravenous drip, intraperitoneal, intramuscular, and intradermal, among others.
-
What are the key molecule types in the Bladder Cancer pipeline products market?
The key molecule types in the Bladder Cancer pipeline products market are Small Molecule, Monoclonal Antibody, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Fusion Protein, Oncolytic Virus, Cell Therapy, Subunit Vaccine, Biologic, and Recombinant Protein, among others.
-
Which are the leading companies in the Bladder Cancer pipeline products market?
Some of the leading companies in the Bladder Cancer pipeline products market are Johnson & Johnson, Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc, Pfizer Inc, F. Hoffmann-La Roche Ltd, Advenchen Laboratories LLC, BioAtla Inc, CG Oncology Inc, and Daiichi Sankyo Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Oncology reports